Related Experiment Videos
TAK-677 (Dainippon/Takeda)
1Stephan.Francke@free.fr
Current Opinion in Investigational Drugs (London, England : 2000)
|December 13, 2002
Summary
TAK-677, a beta3-adrenergic agonist, is being investigated for type II diabetes and obesity. Clinical trials are underway in the US and Japan to evaluate its therapeutic potential.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- TAK-677 is an investigational beta3-adrenergic agonist.
- Developed by Dainippon and Takeda for metabolic disorders.
Purpose of the Study:
- To evaluate TAK-677 for potential treatment of non-insulin dependent diabetes (Type II diabetes).
- To assess TAK-677 for potential treatment of obesity.
Main Methods:
- Phase II clinical trials initiated in March 2001 in the US for Type II diabetes.
- Phase II clinical trials conducted in the US for obesity by December 2001.
- Phase II studies for diabetes conducted in Japan by Dainippon.
Main Results:
- Clinical trial data on efficacy and safety are pending.
- Ongoing investigations in multiple regions.
Conclusions:
- TAK-677 shows promise as a therapeutic agent for Type II diabetes and obesity.
- Further clinical evaluation is necessary to confirm its therapeutic benefits.